MP 4

Drug Profile

MP 4

Alternative Names: Apogen - multiple sclerosis; Apogen MS

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Alexion Pharmaceuticals; National Institutes of Health (USA)
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 02 Feb 2017 Discontinued - Phase-I for Multiple sclerosis in USA (IV)
  • 31 Jan 2003 Suspended - Phase-I for Multiple sclerosis in USA (unspecified route)
  • 09 Dec 2002 Phase-I clinical trials in Multiple sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top